The US FDA and the European Medicines Agency (EMA) are recommending that no new patients with advanced soft tissue sarcoma start treatment with olaratumab (Lartruvo) due to lack of efficacy. The decisions are based on results from the ANNOUNCE study that showed olaratumab in combination with doxorubicin offers no survival benefit over doxorubicin alone. Clinicians may ...
Fast-tracked olaratumab fails to improve sarcoma survival
By Mardi Chapman
30 Jan 2019